Camilla Soenderby has served as an independent director of Abivax since March 2024. She brings 25 years of international biopharma leadership across Europe, the United States and Asia. She serves on the boards of investment company BB Biotech and biotech company F2G, is a member of the Novo Holdings Advisory Group and an industrial advisor to the private-equity group EQT, and previously served on the board of Affibody. She was formerly a corporate officer at Takeda as Chief Patient Value and Product Strategy Officer, led Global Product Strategy at Shire until its acquisition by Takeda, and was Region Head for Roche Pharma and General Manager for Abbott. She began her career as a management consultant at McKinsey & Company and holds a Master's degree from the University of Copenhagen. She chairs the Commercial Committee and is a member of the Remuneration, Science and Clinical, and Nomination and Governance Committees.